The anaphylatoxin C5a exerts a plethora of biologic activities critical in the pathogenesis of systemic inflammatory diseases. Recently, we reported on a C5a mutant, jun/fos-A8, as a potent antagonist for the human and mouse C5a receptor (CD88). Addressing the molecular mechanism accounting for CD88 receptor antagonism by site-directed mutagenesis, we found that a positively charged amino acid at position 69 is crucial. Replacements by either hydrophobic or negatively charged amino acids switched the CD88 antagonist jun/fos-A8 to a CD88 agonist. In addition to CD88, the seven-transmembrane receptor C5L2 has recently been found to provide high affinity binding sites for C5a and its desarginated form, C5adesArg
The anaphylatoxin C5a is generated by proteolytic cleavage of the fifth component of complement (C5). C5a and its degradation product, C5adesArg 74 , exert their various biological activities through interaction with all classes of leukocytes (1) , parenchymal cells of the brain (2) , kidney (3, 4) , liver (5) , and lung (5) , as well as with endothelial cells (6) and smooth muscle cells (7) . C5adesArg 74 has a different spectrum of bioactivity than C5a; for example, stimulation of human basophils by C5a mediates secretion of leukotriene C4, interleukin-4, and interleukin-13, whereas C5adesArg 74 only stimulates the production of interleukin-4 and interleukin-13. Interestingly, C5adesArg 74 is a superagonist for interleukin-13 release (8) .
Until recently, only one C5a receptor (C5aR) 1 had been described (CD88) (9, 10) . CD88 belongs to the large group of seven-transmembrane receptors that signal through both G protein-dependent and -independent pathways (11) . CD88 is able to bind two different classes of G proteins: the pertussis toxin-sensitive G␣ i and the pertussis toxin-insensitive G␣ 16 subunits. Many but not all of the proinflammatory properties of C5a are sensitive to pertussis toxin treatment (1) . Genetic deletion of CD88 protects mice from development of immune complex diseases such as rheumatoid arthritis (12) and immune complex alveolitis (13) , as well as from delayed type hypersensitivity reactions (14) . Interestingly, CD88 deficiency failed to protect against experimental allergic encephalomyelitis (15) , suggesting that in addition to CD88, C5a may signal through other receptors.
Recently, a second C5aR was cloned, C5L2, which also belongs to the family of seven-transmembrane receptors (16, 17) . In contrast to CD88, C5L2 binds both C5a and C5adesArg 74 with high affinity, is uncoupled from G proteins, and lacks receptor internalization (18) . These data were confirmed in a recent publication (19) . Tissue expression of mRNA for human (16, 17, 19) and mouse (19) C5L2 is broad and corresponds well to the expression of CD88. The missing G protein coupling of C5L2 suggests that this receptor may signal through G proteinindependent pathways (11) .
C5aR antagonists (C5aRA) that block the interaction of C5a and C5adesArg with CD88 and C5L2 may prove useful to prevent deleterious biologic activities of C5a without broadly impairing the complement system. Several antagonists for CD88 have been described, including peptides (20 -22) , a nonpeptidic compound (23) , C5a mutants (24 -26) , and anti-C5aR antibodies (27, 28) . All of these compounds are potent CD88 antagonists in vitro; however, only the C5a mutants C5aRAM (24) and jun/fos-A8 (25) , the cyclic peptide AcPhe[L-ornithinePro-D-cyclohexylalanine-Trp-Arg] (AcF-(OpdChaWR)) (29) , and a nonpeptidic antagonist (23) have been proven useful in vivo. Administration of these inhibitors protects animals from in-flammatory responses in immune complex disease (25, 29, 30) , ischemia/reperfusion injury (25, 31, 32) , and C5a-induced neutropenia (23, 24) . The molecular mechanisms underlying the C5aR antagonism are largely unknown. All of these molecules are potent C5aRA for human CD88; however, only the C5a mutant jun/fos-A8 is also a potent antagonist for mouse, rat, and guinea pig CD88. C5aRAM acts as an antagonist for rabbit and micropig CD88 (24) , AcF-(OpdChaWR) acts as an antagonist for rat and dog CD88 (29) , and the nonpeptidic compound acts as an antagonist for gerbil and cynomolgus monkey CD88 (23) .
The ability of these CD88 antagonists to interact with C5L2 remains unknown. The CD88 antagonist jun/fos-A8 was selected from a phage library in which the C terminus of hC5a had been randomly mutated (25) . This C5aRA has been widely used in vitro (25, 33) and in vivo (25, 30, (32) (33) (34) (35) . Six positions are mutated in jun/fos-A8 as compared with C5a: C27A, H67F, D69R, M70S, Q71L, and G73R. In addition, Arg 74 is deleted. Further, parts of the leucine zipper of transcription factor fos are fused N-terminally to A8, forming a heterodimer with parts of the leucine zipper of transcription factor jun, resulting in jun/fos-C5a C27A -(1-66)-FKRSLLR. We assessed the molecular mechanism that renders jun/ fos-A8 a C5aRA by site-directed mutagenesis. Our results provide evidence that position 69 is crucial for CD88 antagonism, whereas both the N-terminal jun/fos moieties and the three C-terminal residues 71-73 are not. Further, we demonstrate that jun/fos-A8 and the deletion mutant A8 ⌬71-73 are potent inhibitors of C5a and C5adesArg 74 binding to C5L2, whereas the peptidic CD88 antagonist AcF-(OPdChaWR) is not. In addition, we present data that CD88 and C5L2 are coexpressed on human monocytes and the human mast cell line HMC-1 but that PMN exclusively express CD88. Table I were constructed by PCR using the pJuFo-⌬ pIII-A8 mutant as template (25) . To obtain fos-C5a
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C27A -(1-66)-FKRSLLR (fos-A8), the jun cassette was deleted by digesting the vector with XhoI and BamHI with 15 units/g DNA at 37°C for 1 h. The digested, linearized vector fragment was run on an agarose gel, and a band at the expected size was cut out and purified using glass milk beads. The purified fragment was religated. The 50-l ligation reaction included 200 ng of digested vector and was incubated overnight at 15°C with 640 units of T 4 -DNA ligase (New England Biolabs) to yield the new vector fragment, pFo⌬pIII-A8. The deletion was confirmed by DNA sequencing.
To obtain C5a C27A -(1-66)-FKRSLLR (A8), the fos cassette was deleted by digesting the pFo-⌬pIII-A8 vector with SacI and KpnI with 15 units/g DNA at 37°C for 1 h. This vector (p⌬JuFo-⌬pIII-A8ϭpA8B) was then used as a template to construct all other C5a mutants. The primer combinations depicted in Table I were used to generate the different A8 mutants.
PCRs were performed in 100-l volumes containing 10 pg of template DNA pA8B, 200 M of each dNTP, 20 pmol of each primer, and reaction buffer supplied by the manufacturer (Stratagene). The reaction mixtures were overlaid with mineral oil and kept at 94°C for 5 min (hot start) in a thermocycler. After adding 5 units of Pfu polymerase (Stratagene), the mixtures were cycled 30 times (94°C for 90 s, 52°C for 120 s, and 72°C for 120 s), followed by incubation at 72°C for 10 min.
After phenol chloroform extraction and ethanol precipitation, the DNA fragments were digested with SacI and KpnI (New England Biolabs) using 60 units/g DNA at 37°C for 1 h. The ligation mix was heat inactivated at 70°C for 30 min, purified by phenol chloroform extraction and ethanol precipitation, followed by resuspension in 5 l of TE (10 mM Tris, 1 mM EDTA). Two portions of 2.5 l each were electroporated into Escherichia coli TG1 cells (Stratagene) using a Bio-Rad pulser set at 25 microfarads, 2.5 kV, and 200 ⍀. Immediately after the pulse, 1 ml of freshly prepared SOC medium (0.5% yeast extract, 2% Tryptone, 10 mM NaCl, 2.5 mM KCl, 10 mM MgCl 2 , 20 mM MgSO 4 , 20 mM glucose) was added, and the cells were grown for 1 h at 37°C and plated on TYE plates (15 g/liter Bacto agar, 10 g/liter Tryptone, 10 g/liter yeast extract, 5 g/liter NaCl) supplemented with 100 g/ml ampicillin and 1% glucose (TYEϩampϩgluc) as described (26) . To score the total number of independent transformants, 100 l of appropriate dilutions were plated onto TYEϩampϩgluc plates.
Purification of C5a Mutants by Immune Affinity Chromatography-TG1 bacteria transfected with pA8 were grown in 2ϫ TYϩamp medium containing 100 g/ml ampicillin and 0.1% glucose. At an A 600 of 0.9, isopropyl-␤-D-thiogalactopyranoside was added to give a final concentration of 0.5 mM. Bacteria were grown overnight with shaking at room temperature. The next day, the periplasmic fraction was prepared by freezing and thawing as described (26) . CNBr-activated Sepharose (Amersham Biosciences) was coated with C5a-specific mAb 561 (36) according to the manufacturer's instructions. A polyethylene-column (Biognosis) was loaded with 100 l of gel matrix. The periplasmic fraction (400 l diluted 1:5 with PBS) prepared from TG1 cells transformed with one of the C5a mutants was applied to the column for 1 h at 4°C. The column was washed with 2 ml of PBS and subsequently loaded with a pre-elution buffer (10 mM phosphate buffer, pH 6.8). Shifting the pH to 2.5 using 100 mM glycin/HCl buffer eluted the bound C5a mutant. Ten 50-l aliquots were collected and subsequently tested in a dot-blot with mAb 561. Positive fractions were pooled. The concentration of purified C5a mutants was determined by enzyme-linked immunosorbent assay. Purified C5a mutants appeared as a single band after separation on 15% SDS-PAGE and subsequent silver staining (data not shown).
Enzyme-linked Immunosorbent Assay to Determine the Concentration of Purified C5a Mutants-The enzyme-linked immunosorbent assay was performed as described previously (36) . Briefly, anti-hC5a-specific mAb 561 was diluted to 10 g/ml in PBS and was coated overnight at 22°C to a polystyrene microtiter plate (Greiner). Then the plates were rinsed three times in PBS and saturated with PBS containing 2% non-fat dry milk for 60 min at 37°C. After washing three times with 50 mM Tris buffer, 0.15 M NaCl, pH 7.5 (Tris), 50 l of the purified C5a mutants diluted in Tris supplemented with 10% non-fat dry milk powder (Tris-milk) were added. After incubation for 90 min at 22°C, the plates were washed four times with Tris and subsequently incubated with 50 l of biotinylated anti C5a mAb 557 (10 g/ml) diluted in Tris-milk for 90 min at 22°C. The plates were washed four times with 50 mM Tris. Subsequently, 50 l of avidin-alkaline-phosphatase diluted in Tris was added and incubated for 30 min at 22°C. The plates were developed with p-nitrophenolphosphate (1 mg/ml diluted in diethanolamine, 5 mM MgCl 2, pH 9).
Competitive Binding Study-Competitive binding studies were performed as described previously (25) . Briefly, 40 l of a reaction mixture 
For all A8 mutants Forward primer 5Ј-A GAG AGA GGT ACC TTA TTA ACG CAA CAG CGA GTC TTT AAA AG-3Ј
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containing a constant amount of 125 I-rhC5a as tracer (0.1 nM; Ϸ17,000 cpm) and increasing concentrations of unlabeled C5a mutants were incubated in a microtiter plate on ice. The binding reaction was started by adding 25 l of ice-cold CD88-transfected RBL-2H3 (CD88-RBL) cell suspension (37) . After incubation on ice for 30 min, cell-bound and free 125 I-rhC5a were separated by filtration of 60 l through a microtitration membrane plate (Multiscreen HV; 0.45 m, Millipore) using a vacuum manifold (Millipore). The wells were washed out once with 100 l of HAG-CM buffer (20 mM HEPES, pH 7.4, 125 mM NaCl, 5 mM KCl, 1 mM CaCl 2 , 1 mM MgCl 2 , 0.25% bovine serum albumin, and 0.5 mM glucose), dried by a heat lamp, and punched out with a membrane punch assembly. The punched out membranes were counted in a ␥-counter (Packard). The plot of cell-bound 125 I-rhC5a versus the concentration of unlabeled competitor yielded the half-maximal inhibitory concentrations (IC 50 ).
Cellular Activation and Inhibition Assays-The release of N-acetyl-␤-D-glucosaminidase from CD88-transfected RBL cells was determined as described (26) . The ED 50 of rhC5a (Sigma-Aldrich) and C5a mutants was determined as the concentration leading to half-maximal enzyme release. The antagonistic potency of the different C5aRAs was tested as their ability to inhibit the release of N-acetyl-␤-D-glucosaminidase from CD88-transfected RBL cells induced by 10 Ϫ9 M C5a. Briefly, 75 l/well of CD88-transfected RBL cells (2 ϫ 10 6 /ml) were suspended in HAG-CM buffer and equilibrated for 5 min at 37°C. Meanwhile, 20 l of serial dilutions of the purified C5a mutants were transferred to a microtiter plate (Greiner) and incubated for 5 min at 37°C. After 5 min of preincubation, cytochalasin B (20 g/ml) was added to the cells and incubated for 3 min at 37°C. Subsequently, the cells were transferred to the C5aRA and incubated for 10 min at 37°C. Then rhC5a was added at a final concentration of 10 Ϫ9 M, and the reaction was allowed to proceed for 5 min at 37°C. The reaction was stopped by centrifugation at 1157 ϫ g for 3 min at 4°C. Subsequently, 75 l of the supernatant were mixed with 100 l of substrate (p-nitrophenyl-N-acetyl-␤-D-glucosaminide). The reaction was stopped by adding 75 l of glycine/NaOH, pH 10.4/ well. The absorbance (405 nm) was determined in an enzyme-linked immunosorbent assay reader. The ID 50 of the C5a mutants was determined as the concentration leading to inhibition of half-maximal enzyme release induced by 10 Ϫ9 M rhC5a.
Fluorescent Labeling of jun/fos-C5aAla27-jun/fos-C5a
C27A was labeled with FLUOS (Roche Applied Science) at a molar ratio of 1:10 (ligand to FLUOS) for 1 h at room temperature according to the manufacturer's recommendations. Labeled ligand was separated from free FLUOS on a Sephadex G25 M column. As demonstrated previously, jun/fos-C5a C27A exhibits the same binding properties and functional potency as rhC5a (38) .
Generation of FLUOS-jun/fos-C5a
C27A
-desArg
-To cleave off the C-terminal arginine, FLUOS jun/fos-C5a
C27A was treated with carboxypeptidase B (Calbiochem) (5 units/mg) for 15 min at 37°C as we have described previously (39) .
Flow Cytometric Analysis of Agonist and Antagonist Binding to CD88 and C5L2-To assess the specific binding of rhC5a, the different A8 mutants, and AcF-(OpdChaWR) to CD88-RBL cells or C5L2-transfected CHO (C5L2-CHO) cells (18), 5 ϫ 10 5 cells (in 50 l) were incubated with FLUOS-jun/fos-C5a C27A (1 ϫ 10 Ϫ8 M) in the presence of increasing concentrations of the respective molecules for 12h at 4°C in PBS supplemented with bovine serum albumin (1%). The ability of the C5a mutant A8
⌬71-73
and AcF-(OpdChaWR) to inhibit binding of C5adesArg 74 to CD88 or C5L2 was tested by incubating CD88-RBL-2H3 cell and C5L2-CHO cells with jun/fos-C5a C27A -desArg 74 (5 ϫ 10 Ϫ8 M) in the presence of increasing concentrations of the respective C5aRA. Subsequently, the cells were pelleted, washed three times with 200 l of PBS, and resuspended in 4% paraformaldehyde in PBS for fluorescence-activated cell scanning analysis.
Flow Cytometric Analysis of CD88 and C5L2 Expression on Human PMN, Monocytes, and HMC-1 Cells-Human monocytes were isolated by countercurrent elutriation (40) from healthy volunteers. Human neutrophils were isolated from healthy volunteers by density centrifugation from EDTA plasma using Polymorphprep TM (Nycomed) according to the manufacturer's recommendations. Purity of PMN was Ͼ95% as determined microscopically using Diff-Quick staining (Baxter). PMN, monocytes, or HMC-1 cells (1 ϫ 10 6 cells) were incubated with either anti-CD88 mAb 5S/1 (10 g/ml) (kindly provided by Dr. O. Götze, Göttingen, Germany) (27) or the protein A-purified polyclonal rabbitanti-C5L2 antibody (5 g/ml) described earlier (41) for 60 min at 4°C in 100 l of PBS-bovine serum albumin (1%). The purified polyclonal rabbit-anti-C5L2 antibody does not bind to untransfected RBL cells or RBL cells transfected with CD88, hC3aR, human formyl peptide receptor-like 1/lipoxin A4 receptor (FPRL1/LXA4R), or ChemR23 (42).
2 Isotype-matched control antibodies (IgG2a (10 g/ml) or protein A-purified rabbit nonimmune polyclonal antibody (5 g/ml)) were used as controls. In some experiments, the specificity of C5L2 binding by polyvalent rabbit anti-C5L2 antibody binding was assessed in the presence of the immunizing peptide (1 g/ml) as described (41) . The cells were washed twice in 200 l of PBS and incubated with either fluorescein isothiocyanate-labeled anti-mouse or anti-rabbit antibody (PharMingen) for 60 min at 4°C. After two additionally washes, the cells were resuspended in 200 l of PBS (4% paraformaldehyde) for fluorescence-activated cell scanning analysis.
RESULTS
N-terminal Deletion of the jun/fos Leucine Zipper Improves
Binding and Functional Activity-The jun/fos-A8 mutant is expressed from a bicistronic vector that encodes the leucine zipper of transcription factor jun and the leucine zipper of transcription factor fos fused to C5a
C27A -(1-66)-FKRSLLR, i.e. fos-C5a
C27A -(1-66)-FKRSLLR (38) . When expressed in E. coli, jun and fos form a heterodimer. To assess the impact of the jun-leucine zipper and the N-terminally fused fos-zipper moiety on CD88 binding and function, jun as well as jun/fos were deleted, resulting in the two C5a mutants fos-A8 and A8, respectively. Binding potency of fos-A8 to CD88-transfected RBL-2H3 cells as well as its ability to inhibit C5a-induced enzyme release slightly increased as compared with jun/fos-A8 ( Fig. 1 and Table II ). However, deletion of both jun and fos significantly increased C5a receptor binding (IC 50 (Fig. 1) , suggesting that the fos moiety negatively impacts the interaction of the C5a mutant with CD88. Table II ).
Impact of C-terminal Mutations or Deletions on CD88 Binding and
Next, we tested whether the C-terminal arginine residue contributes to CD88 receptor binding and/or antagonistic potency by replacing it by either a tyrosine (A8 S70L,R73Y ) or cysteine residue (A8 R73C ). These replacements affected neither the IC 50 nor the ID 50 , suggesting that position 73 is not necessary for CD88 binding and antagonistic properties of A8 (Fig. 2 and Table II) .
To assess the impact of the two leucine residues at positions 71 and 72, we constructed two C-terminal deletion mutants. In the first mutant, positions 72 and 73 were deleted, and the leucine residue at position 71 was replaced by a cysteine residue resulting in A8 L71C,⌬72-73 . The rationale for the L71C replacement were data obtained by Pellas et al. (24) suggesting that a C-terminal cysteine residue at position 71 is important for antagonistic properties of C5a mutants. Interestingly, the IC 50 and the ID 50 of this mutant (A8 L71C,⌬72-73 ) were 4-fold higher as compared with A8 (p Ͻ 0.001, ANOVA; Fig. 2 and Table II ). To determine whether the deletion of residue 72 or the L71C replacement accounted for the loss in binding and antagonistic potency, the cysteine residue at position 71 was deleted resulting in A8 ⌬71-73 . Interestingly, the IC 50 and the ID 50 of A8 ⌬71-73 were indistinguishable from A8, suggesting that positions 71-73 are not necessary for CD88 binding and antagonism ( Fig. 2 and Table II) .
Positively Charged Amino Acids at Position 69 Are Crucial for CD88 Antagonism-After ruling out positions 70 -73 as being critical for CD88 antagonism, positions 67-69 were considered candidates contributing to the antagonistic activity of A8. However, our previous data and data from literature suggested that amino acids at positions 67 and 68 contribute to 
L72C,⌬72-73
a Highest concentration that was used in the assay. b AcF, phenylalanine with N-terminal acetylation. c dCha, D-cyclohexylalanine.
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CD88 binding and agonist activity (43) (44) (45) (46) . Thus, we focused on position 69 and evaluated whether the arginine residue might account for the observed C5aR antagonism of A8. First, the cationic arginine residue was replaced by the cationic lysine residue. This replacement increased the IC 50 (Table II) . Next, we replaced Arg 69 by the hydrophobic alanine residue. Intriguingly, this exchange destroyed the antagonistic property of A8, suggesting that the positive charge at position 69 is crucial. In fact, A8 R69A was a potent C5aR agonist with an ED 50 of 36.8 Ϯ 2.9 nM (Fig.  3 , A and C, and Table II) . However, binding to CD88 was essentially unchanged as compared with A8 (Table II) . These data suggest that position 69 is not a binding residue; however, a positive charge at that position prevents C-terminal amino acids interacting with CD88 sites that trigger signaling and/or formation of CD88 dimers or oligomers (47) , which may be important for CD88 signaling. Finally, the positive charge at position 69 was replaced by the negatively charged aspartic acid residue (which is native to C5a). This mutant (A8 R69D ) was a pure C5aR agonist (Fig. 3 , B and C) with ID 50 and ED 50 values almost identical to those of rhC5a (Table II) .
The C5aRA A8
⌬71-73 but Not AcF-(OpdChaWR) Inhibits Binding of C5a/C5adesArg
74 to C5L2-In addition to CD88, C5a and C5adesArg 74 bind to C5L2 (18, 19) . Because all of the highly conserved binding residues in the core region of C5a are preserved in the C5a mutants, we wondered whether A8 or A8 ⌬71-73 might bind to C5L2 as well. Because A8 and A8
⌬71-73
showed the same behavior in the binding experiments outlined below, only data obtained with A8 ⌬71-73 are shown. A8
dose-dependently blocked FLUOS-labeled jun/fos-C5a
C27A binding to CD88-RBL cells and to C5L2-CHO cells (Fig. 4, A  and B) . In contrast, no inhibition of C5a binding to C5L2 was found using the peptidic CD88 antagonist AcF-(OpdChaWR) (Fig. 4A) , which, however, potently blocked C5a binding to and signaling through CD88 in CD88-RBL cells (Fig. 4A and Table  II ).
The binding affinity of hC5adesArg 74 to CD88 is 20 -100-fold lower as compared with hC5a (18, 19) . In contrast, C5L2 provides a high affinity binding site for hC5adesArg 74 , the IC 50 of which is only 2-5-fold lower as compared with hC5a (18, 19 C27A -desArg (5 ϫ 10 Ϫ8 M) to C5L2 by 75%, whereas AcF-(OpdChaWR) (5 ϫ 10 Ϫ6 M) had no effect (Fig. 4C) .
Expression of CD88 and C5L2 on Human PMN, Monocytes, and the Human Mast Cell Line HMC-1-CD88 and C5L2 mRNAs are abundantly expressed in several tissues and in peripheral blood leukocytes (16, 17, 19) , suggesting coexpression of both receptors. To determine whether mRNA expression corresponds to protein expression on the cell surface, three different immunocompetent leukocyte populations were studied by flow cytometry: PMN, monocytes, and the human mast cell line HMC-1. PMN from three different healthy donors stained highly positive for CD88; however, we did not find any positive staining for C5L2 (Fig. 5A) . On monocytes and HMC-1 cells, we found a homogeneous expression of both CD88 and C5L2 (Fig. 5, B and C) . However, the signal intensity of C5L2 staining on monocytes was much lower as compared with that of CD88 (Fig. 5B) . This may be due to lower receptor numbers or may simply reflect different affinities of CD88 and C5L2 antibodies. Further, C5L2 (but not CD88) expression on monocytes of four different healthy donors was highly variable ( Fig.  5B ; median fluorescence intensities were 7.3-24.3). In contrast, we found strong C5L2 and CD88 staining on HMC-1 cells, suggesting expression of high receptor numbers of both CD88 and C5L2 (Fig. 5C ).
An almost identical intensity of CD88 and C5L2 staining was found on CD88-transfected RBL-2H3 cells and C5L2-transfected CHO cells (data not shown), suggesting that the differences in C5L2 and CD88 staining on monocytes rather reflect lower receptor numbers than different antibody affinities and/or limiting concentrations of anti-C5L2 antibodies. 
DISCUSSION
Recent studies modeling pulmonary infection, sepsis, autoimmune disease, and ischemia/reperfusion injury in mice and rats suggest that agents blocking C5a effector functions may provide potent therapeutics in humans. Several agents have been developed that block the interaction of C5a with CD88, most of which, however, lack in vivo activity (48), suffer from being partial agonists, and/or appear to be cytotoxic (49) . Recently, C5a mutants (24, 25) , a cyclic peptide (22, 29) , and a nonpeptidic compound (23) have been described that block C5a activity in vivo. We previously selected the C5a mutant jun/ fos-A8 from a phage library, in which the C-terminal positions 69 -73 had been randomly mutated (25) . jun/fos-A8 turned out to be a potent and specific C5aRA, blocking C5a activities in vitro (25, 33) and in vivo (25, 30, 32-35) . However, the mechanisms underlying the C5aR antagonism remained unclear.
C5a and C5adesArg 74 binding to CD88 is complex. Sitedirected mutagenesis studies in which either C5a (44, 50, 51) , CD88 (52, 53), or both (54, 55) were mutated provide evidence that the C-terminal amino acids from positions 65-74 confer binding and agonist activity. The core segment, comprising the remainder of the C5a molecule, contributes significantly to high affinity binding but not to biologic activity. In search of the mechanism that renders jun/fos-A8 a CD88 antagonist, we focused primarily on the N-terminal jun/fos heterodimer. Knowledge of the structure-activity relationships for C5a suggested an interaction of the N-terminal jun/fos heterodimer (comprising 80 amino acids) with the C-terminal tail of jun/ fos-A8 as a means to disrupt its interaction with CD88. In fact, several aspartic acid residues within the leucine zippers could ), or Lys 69 (A8 R69K ) and tested for their ability to induce enzyme release. The enzyme release is given in percentages. B, CD88-transfected RBL cells were incubated with different concentrations of A8 or the A8 mutant A8 R69K for 10 min at 37°C and subsequently challenged with rhC5a (1 ϫ 10 Ϫ9 M). The inhibition of the C5a-induced enzyme release is given in percentages. C, effect of amino acid replacements at position 69 on CD88 antagonism and agonism. A positively charged amino acid at position 69 (either Arg or Lys; black bars) renders A8 a pure C5aR antagonist with an ID 50 in the low nanomolar range; replacement of the positive charge by a hydrophobic or a negatively charged amino acid transforms A8 from a CD88 antagonist into a CD88 agonist (black versus white bars). The data are the means Ϯ S.E. of multiple experiments (n ϭ 3-4). **, p Ͻ 0.001 A8 R69K versus A8 (t test); ϩϩ, p Ͻ 0.001 A8 R69A versus rhC5a (ANOVA).
potentially interact with the two positively charged residues, Arg 69 and Arg 73 , in jun/fos-A8. However, deletion of one or both leucine zippers did not negatively impact the antagonistic potential of the A8 mutant. Rather, deletion of jun and fos improved antagonism and binding to CD88, suggesting some impact of the C terminus of A8.
The facts that the C terminus confers C5a activity and that only amino acids 69 -71 had been mutated in the phage library from which A8 was selected led to experiments that tested alternative C-terminal amino acids. Neither amino acid substitutions at position 70 or 73 nor deletion of amino acids at positions 71-73 had a negative impact on CD88 antagonism or CD88 binding. A cysteine residue at position 70, as in C5a M70C,⌬71-74 , or at position 71, as in C5a Q71C,⌬72-74 , had previously been reported as being crucial for C5aR antagonism of C5a mutants (24) . Thus, we assessed whether deletion of amino acids 72 and 73 combined with a L71C replacement improves the antagonistic potency of A8. Surprisingly, we found a 4-fold decrease in antagonistic and binding potency, suggesting that the interaction of C71 with CD88 acted contrary to the mechanisms that renders A8 a CD88 antagonist. Further, it is noteworthy that A8 (C5a C27A, H67F,D69R,M70S ) is an antagonist for human and murine CD88, whereas C5a Q71C,⌬72-74 and C5a M70C,⌬71-73 (24) are antagonists for human but not for murine CD88 (but for rabbit and micropig CD88). These data point to the importance of C-terminal amino acid composition for species-specific CD88 binding because they provide evidence that subtle changes in the composition of C-terminal amino acids (positions 67, 69, and/or 70) are sufficient to change the species specificity of C5a mutants.
After ruling out both N-terminal addition of jun/fos and C-terminal amino acids at positions 70 -73, the D69R replacement at position 69 remained as a candidate responsible for CD88 antagonism of A8. Of note, position 69 is not conserved between species and was not considered as a binding residue in site-directed mutagenesis studies (44, 50) . However, the posi- tive charge at position 69 turned out to be essential for CD88 antagonism. In fact, replacement of Arg 69 by the hydrophobic alanine residue or the negatively charged glutamic acid residue switched antagonism to agonism. Interestingly, the R69A replacement did not change the binding properties of A8 (35. . 56) . Further, the critical importance of a positive charge for receptor antagonism appears to depend on the composition of the neighboring amino acids, because the D69K replacement within C5a results in a pure agonist in which both binding and biologic activity are essentially unchanged (44) .
The pleiotropic functions of C5a, such as modulation of cytokine release (1), regulation of apoptosis (57, 58) and tissue regeneration (59), along with different spectra of C5a and C5adesArg 74 bioactivities, suggest that CD88 couples to different signaling pathways and/or that C5a and C5adesArg 74 bind and signal through an additional receptor. Coupling of CD88 to G␣ i and G␣ 16 subunits has been described; however, knowledge of CD88 signaling and the linkage between signaling and effector functions is rather sketchy. Recently, a second C5a/ C5adesArg 74 -binding protein was discovered, C5L2, the mRNA expression of which is remarkably similar to that of CD88. Of note, C5L2 receptors are expressed on immature (but not mature) dendritic cells, and abundant C5L2 mRNA expression occurs in the spleen (16) . These data suggest that C5L2 may have immunomodulatory functions on immature dendritic cells. Interestingly, C5L2 has high affinity binding sites for both C5a and C5adesArg 74 , whereas C5adesArg 74 binding to CD88 is poor (20 -100-fold lower as compared with C5a). Under circumstances in which the complement system is activated in the circulation (e.g. during sepsis), C5a is rapidly converted to C5adesArg 74 by carboxypeptidases R and N (60) and will preferentially bind to C5L2. C5L2 does not follow the classical scheme of seven-transmembrane receptor activation, because it does not couple to G proteins and is not internalized on ligand binding (18, 19) . However, C5a induces receptor phosphorylation of C5L2, although the signal intensity is much weaker compared with that of CD88 (19) . Unfortunately, C5adesArg 74 , which behaves as a superagonist for some bioactivities (8), was not tested by these authors. Altogether these data suggest that C5L2 may use alternative, G protein-independent pathways for signaling as recently described for a panel of seven-transmembrane receptors (reviewed in Ref. 11). Consequently, it may prove useful to block binding of both C5a (and C5adesArg 74 ) to CD88 and of C5adesArg 74 (and C5a) to C5L2. We tested the ability of the two most widely used C5aRAs, i.e. A8 and the cyclic C5a C-terminal analog peptide AcF-(OPdChaWR), to block binding of C5a or C5adesArg 74 to CD88 and C5L2. In particular we focused on A8 ⌬71-73 , because among all mutants, A8 ⌬71-73 is most similar to C5a differing only at four positions (C27A, H67F, D69R, and M70S). As shown in Fig. 4, A8 ⌬71-73 , but not AcF-(OPdChaWR), inhibits both C5a and C5adesArg 74 binding to CD88 and C5L2. Interestingly, the agonistic C5a analog hexapeptide FKAdChaChadR has recently been described to displace C5a from CD88 and C5L2 with an almost identical affinity (19) . However, the apparent affinities of FKAdChaChadR to CD88 (1.8 ϩ 0.7 ϫ 10 Ϫ5 M) and C5L2 (2.7 ϩ 0.9 ϫ 10 Ϫ5 M) calculated by these authors are 1000-fold lower as compared with the IC 50 values that we determined for AcF-(OPdChaWR) to CD88 (2.21 ϩ 0.18 ϫ 10 Ϫ8 M; 50 for C5L2, 5.84 ϫ 10 Ϫ5 M). Thus, the C5a analog peptide FKAdChaWR binds to CD88 and C5L2; however, its binding potency is very low. These data suggest that the core segment of C5a (amino acids 1-64) provides most of the binding energy to both CD88 and C5L2, whereas the contribution of the C5a C terminus is only marginal. Further, amino acid substitutions that improve binding affinity toward CD88 (FKAdChaChadR versus AcF-(OPdChaWR)) have no measurable effect on C5L2 binding, suggesting that the interactions of the C5a C terminus with CD88 and C5L2 are different.
C5L2 mRNA expression appears to be most abundant in peripheral leukocytes. PMN and monocytes represent two important cell types of this population mediating bacterial defense and inflammation. Both populations express CD88 in high numbers (1) . We assessed whether these cells express C5L2 as well. Interestingly, we found no expression of C5L2 on PMN of three different healthy donors. The missing expression of C5L2 on PMN is in contrast to data obtained in a recent publication. These authors found coexpression of CD88 and C5L2 in approximately equal numbers (19) . These differences may be explained by the regulation of C5L2 expression through different PMN purification protocols or by different donors. On monocytes, CD88 and C5L2 were coexpressed, although the expression level of C5L2 was lower as compared with CD88 and varied substantially from donor to donor (Fig. 5B ). It will be interesting to see in further studies whether C5L2 expression is modulated by local or systemic inflammation. In addition to peripheral leukocytes, CD88 is expressed on skin, cardiac, and synovial mast cells and the human mast cell line HMC-1 (61, 62) . Surprisingly, and in contrast to PMN and monocytes, we found strong and homogeneous C5L2 expression on HMC-1 cells (Fig. 5C ). These data fit well with results by Werfel et al. (63) showing that C5a but not C5adesArg 74 induced transient mobilization of intracellular calcium in HMC-1 cells, whereas both C5a and C5adesArg 74 induce transient mobilization of intracellular calcium in PMN. Because PMN express only CD88 but not C5L2, C5a and C5adesArg 74 exclusively signal through CD88, resulting in mobilization of intracellular calcium. However, in HMC-1 cells C5adesArg 74 will preferentially bind to C5L2, which does not to trigger calcium mobilization (18, 19) .
In summary, we have identified a positively charged amino acid at position 69 as being crucial for the CD88 antagonism of the C5a mutant A8. Further, we have found that A8 and A8 ⌬71-73 (but not the cyclic peptidic AcF-(OPdChaWR)) are potent inhibitors of C5a and C5adesArg 74 binding to C5L2. Finally, we demonstrate differential expression of CD88 and C5L2 on human PMN, monocytes, and HMC-1 cells. The fact that A8
⌬71-73 is structurally very similar to C5a, blocks C5a and C5adesArg 74 binding to the two known C5aRs, and is a powerful C5aRA in animal models of inflammation suggests that A8
⌬71-73 may be a useful therapeutic agent to target C5a/C5adesArg 74 bioactivities in humans.
